Revvity Inc vs ProShares Ultra Semiconductors — how do they compare? Revvity Inc trades at $152.05 (market cap $16.98B), while ProShares Ultra Semiconductors trades at $98.9 (market cap $2.94B). The key difference: Revvity Inc is far larger — about 5.8× ProShares Ultra Semiconductors's market cap, and Revvity Inc pays a 0.18% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and ProShares Ultra Semiconductors for 29 Days on average.
| RVTY | USD | |
|---|---|---|
Market Cap | $16.98B | $2.94B |
Volume | 1,456,900 | 630,148 |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.36 | $113.53 |
52-Week Low | $82.26 | $43.19 |
Typical Hold Time | 12 Days | 29 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →